Autologous mRNA-transfected Anti-BCMA-CAR T-lymphocytes SYS6020

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation consisting of autologous T-lymphocytes that have been transfected with lipid nanoparticle (LNP)-mRNA encoding for a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and containing as of yet undisclosed co-stimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, autologous mRNA-transfected anti-BCMA-CAR T-lymphocytes SYS6020 specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.

**Synonyms:** - Autologous BCMA-targeted CAR T-cells SYS6020 - Autologous mRNA-LNP-based Anti-BCMA CAR-T Cells SYS6020 - Autologous mRNA-Lipid Nanoparticles-based Anti-BCMA CAR T-cells SYS6020 - SYS 6020 - SYS-6020 - SYS6020